Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Bailard Inc.

Bailard Inc. reduced its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 1.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 666,108 shares of the biopharmaceutical company's stock after selling 6,801 shares during the period. Gilead Sciences accounts for about 1.9% of Bailard Inc.'s investment portfolio, making the stock its 8th largest position. Bailard Inc. owned about 0.05% of Gilead Sciences worth $74,637,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Smallwood Wealth Investment Management LLC purchased a new position in shares of Gilead Sciences during the 1st quarter worth about $25,000. Goodman Advisory Group LLC purchased a new position in shares of Gilead Sciences during the 1st quarter worth about $29,000. Core Alternative Capital lifted its holdings in shares of Gilead Sciences by 370.8% during the 1st quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock worth $34,000 after acquiring an additional 241 shares during the period. Annis Gardner Whiting Capital Advisors LLC lifted its holdings in shares of Gilead Sciences by 158.8% during the 4th quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company's stock worth $33,000 after acquiring an additional 216 shares during the period. Finally, Investment Research & Advisory Group Inc. lifted its holdings in shares of Gilead Sciences by 33.3% during the 1st quarter. Investment Research & Advisory Group Inc. now owns 400 shares of the biopharmaceutical company's stock worth $45,000 after acquiring an additional 100 shares during the period. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction on Monday, July 14th. The shares were sold at an average price of $109.74, for a total value of $548,700.00. Following the completion of the transaction, the director owned 8,920 shares of the company's stock, valued at $978,880.80. The trade was a 35.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction on Tuesday, July 15th. The stock was sold at an average price of $111.03, for a total transaction of $277,575.00. Following the completion of the transaction, the chief financial officer directly owned 162,610 shares of the company's stock, valued at approximately $18,054,588.30. This represents a 1.51% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 72,000 shares of company stock worth $7,844,775. Company insiders own 0.27% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. Cantor Fitzgerald began coverage on shares of Gilead Sciences in a report on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 price objective on the stock. Oppenheimer cut their price target on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a report on Friday, April 25th. JPMorgan Chase & Co. raised their price target on shares of Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a report on Thursday, March 27th. Morgan Stanley raised their price target on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a report on Friday, April 25th. Finally, Needham & Company LLC restated a "hold" rating on shares of Gilead Sciences in a report on Wednesday, May 21st. Nine research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat, Gilead Sciences presently has a consensus rating of "Moderate Buy" and an average target price of $111.38.

Gilead Sciences Stock Down 0.5%

Shares of GILD stock traded down $0.58 during mid-day trading on Friday, reaching $108.22. 6,627,889 shares of the company were exchanged, compared to its average volume of 7,666,525. Gilead Sciences, Inc. has a fifty-two week low of $70.78 and a fifty-two week high of $119.96. The company has a debt-to-equity ratio of 1.16, a quick ratio of 1.23 and a current ratio of 1.37. The company has a market capitalization of $134.62 billion, a P/E ratio of 22.78, a P/E/G ratio of 0.71 and a beta of 0.29. The business's 50 day simple moving average is $108.58 and its 200 day simple moving average is $105.06.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. The business had revenue of $6.67 billion during the quarter, compared to the consensus estimate of $6.77 billion. During the same quarter last year, the company earned ($1.32) earnings per share. The business's quarterly revenue was down .3% compared to the same quarter last year. Research analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 27th. Shareholders of record on Friday, June 13th were issued a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 2.92%. The ex-dividend date was Friday, June 13th. Gilead Sciences's dividend payout ratio is presently 66.53%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.